The Dark Side of Antibiotics

Why the CDC is advising hospitals to scale back on prescriptions.

National Journal
Add to Briefcase
Brian Resnick
March 5, 2014, midnight

The Cen­ters for Dis­ease Con­trol and Pre­ven­tion wants hos­pit­als to is­sue few­er pre­scrip­tions for an­ti­bi­ot­ics. Why? Be­cause the drugs that are sup­posed to make people feel bet­ter are be­ing ab­used, ac­tu­ally caus­ing ill­ness, and hasten­ing the ar­rival of in­fec­tions for which medi­cine has no cure.

That’s not to say the CDC wants to cut the drugs from treat­ment en­tirely. A bac­teri­al in­fec­tion still re­quires an­ti­bi­ot­ics. Rather, the CDC wants to stifle the ap­prox­im­ately 30 per­cent to 50 per­cent of an­ti­bi­ot­ic treat­ments that the or­gan­iz­a­tion deems un­ne­ces­sary or in­ap­pro­pri­ate. The CDC also want doc­tors to make smarter dos­ing de­cisions when an­ti­bi­ot­ic use is ap­propi­ate. 

An­ti­bi­ot­ics can cause CDI (C. dif­fi­cile in­fec­tion), a diarrhea “that of­ten re­curs and can pro­gress to sepsis and death,” as the CDC re­port re­leased Tues­day reads. CDI oc­curs when an­ti­bi­ot­ics throw off the nat­ur­al bal­ance of healthy bac­teria in the di­gest­ive tract.

In the study, the CDC pre­dicted that de­creas­ing an­ti­bi­ot­ic use by 30 per­cent would lead to a 26 per­cent de­crease in CDI. By the CDC’s es­tim­ate, that would im­prove the out­comes of 65,000 people. Fur­ther­more, the cen­ter found that one in three pre­scrip­tions for ur­in­ary tract in­fec­tions con­tained a po­ten­tial er­ror (“giv­en without prop­er test­ing or eval­u­ation, or giv­en for too long”), and some hos­pit­als pre­scribe an­ti­bi­ot­ics at rates three times as high as oth­ers.

But those prob­lems seem small when you con­sider the loom­ing threat of the over­use of an­ti­bi­ot­ics — the rise in dis­eases that do not re­spond to the drugs at all.

As re­por­ted in Septem­ber, the CDC es­tim­ates that 23,000 people a year die of such dis­eases. And bar­ring in­nov­a­tion in phar­ma­ceut­ic­als (which is lag­ging far be­hind ad­vance­ments in oth­er cat­egor­ies of drugs) or re­duc­tion ef­forts as out­lined in this cur­rent re­port, that num­ber is likely to rise.

The CDC is head­ing up an ef­fort to bet­ter track the spread of an­ti­bi­ot­ic res­ist­ance, and the Obama ad­min­is­tra­tion’s 2015 budget provides $30 mil­lion over the next five years to set up re­gion­al labor­at­or­ies to mon­it­or out­breaks.

There’s an in­ev­it­ab­il­ity to drug-res­ist­ant bac­teria, even with new ad­vances in the sci­ence. “Nature will take its course wherever an­ti­bi­ot­ics are used,” Jean Pa­tel, a re­search­er in mi­cro­bi­al res­ist­ance at the CDC, told me in Septem­ber. 

But the phar­ma­ceut­ic­al in­dustry is not even pro­du­cing those new drugs that could buy some time.

As The At­lantic demon­strates in its March is­sue, ap­provals of new an­ti­bi­ot­ic drugs are at their low­est levels in 30 years.

(The Atlantic) The Atlantic

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.